Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. (TPST) is a biotechnology company focused on the development of small molecule therapeutics that modulate anti-tumor immunity pathways.
Tempest's mission is to pioneer novel treatments for cancer by leveraging a balanced and deep pipeline of small molecule therapeutics. These therapeutics are designed to modulate distinct immune response pathways that are crucial for mounting an effective anti-tumor response. Developed by Inception Sciences, a Versant Ventures-affiliated drug discovery engine, the company’s pipeline includes first-in-class and best-in-class molecules.
The company’s leading product candidates, TPST-1120 and TPST-1495, are in the clinical stage. TPST-1120 aims to inhibit its target to promote anti-tumor immunity, while TPST-1495 is designed to activate tumor-specific immune responses. These candidates are developed to address significant unmet medical needs across a range of cancers.
Tempest Therapeutics has assembled a highly experienced team of drug developers specializing in small molecules and immuno-oncology. This team is dedicated to advancing these programs through clinical trials and eventually to market. The company's robust research and development efforts are backed by a syndicate of leading venture capital firms based in the United States and China, providing strong financial support and strategic guidance.
Recent achievements for Tempest Therapeutics include the initiation and progress of randomized clinical trials, showcasing the company’s commitment to evidence-based development and regulatory approval. With a focus on innovation and patient outcomes, Tempest Therapeutics is well-positioned to make significant contributions to the field of oncology.
For more detailed information on the company’s latest updates, news, and financial performance, you can contact Sylvia Wheeler and Aljanae Reynolds at Wheelhouse Life Science Advisors.
Tempest Therapeutics (Nasdaq: TPST) presented promising preclinical data on April 8, 2022, regarding its innovative therapeutic programs at the AACR Annual Meeting. The data highlight the anti-tumor efficacy of TPST-1495, a dual antagonist targeting EP2 and EP4 receptors, showing superior tumor growth inhibition compared to single antagonists. Additionally, the TREX1 inhibitors demonstrated significant potential in activating the cGAS/STING pathway, crucial for immune response in tumors. These findings support ongoing clinical studies and underscore Tempest's commitment to developing first-in-class oncology treatments.
Tempest Therapeutics, Inc. (TPST) reported its financial results for 2021, highlighting significant achievements, including a successful merger and collaboration with Roche for TPST-1120. The company ended the year with $51.8 million in cash, a notable increase from $18.8 million in 2020. However, it recorded a net loss of $28.3 million, or $7.47 per share. R&D expenses rose to $17.2 million, indicating increased investment in drug development. Tempest anticipates presenting initial clinical data for TPST-1120 and TPST-1495 by early 2023, showcasing its robust cancer therapeutics pipeline.
Tempest Therapeutics (Nasdaq: TPST) announced its participation in the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 10:40 a.m. ET. The company is focused on developing first-in-class therapeutics that integrate targeted and immune-mediated mechanisms for various tumors. Its clinical-stage programs, TPST-1120 and TPST-1495, are currently in Phase 1 trials. The company collaborates with F. Hoffmann La Roche for a global Phase 1b/2 study of TPST-1120 in advanced liver cancer patients. More details can be accessed at Tempest's investor site.
Tempest Therapeutics (Nasdaq: TPST) announced two poster presentations at the 2022 AACR virtual annual meeting scheduled for April 8-13, 2022. The presentations feature new preclinical data on TPST-1495, a clinical-stage dual EP2/4 antagonist, and TREX1, a preclinical STING agonist. Key presentations include: TPST-1495 focusing on the dual blockade of PGE2 receptors and TREX1 aimed at activating STING in metastatic disease. Both programs are designed to enhance tumor treatment via targeted and immune-mediated approaches.
Tempest Therapeutics, a clinical-stage oncology company (Nasdaq: TPST), announced its participation in the 11th Annual SVB Leerink Healthcare Conference on February 16, 2022, at 2:20 PM ET. The company is known for developing innovative therapeutics that target tumors and harness immune responses. Presently, it is advancing two main programs, TPST-1120 and TPST-1495, through Phase 1 studies. TPST-1120 is also involved in a global Phase 1b/2 study in combination with atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma. More details are available on their website.
Tempest Therapeutics (Nasdaq: TPST) announced the initiation of patient dosing with TPST-1495 in combination with pembrolizumab. This Phase 1a/1b study aims to optimize dosing schedules for patients with solid tumors. TPST-1495 targets the PGE2 pathway, which is linked to tumor growth and immune suppression. The study will evaluate safety, tolerability, and preliminary anti-tumor activity, focusing on prostaglandin-driven cancers. Tempest is exploring TPST-1495's potential to enhance treatment outcomes when combined with existing therapies.
Tempest Therapeutics (TPST) presented data at the 2021 Society for Immunotherapy of Cancer Annual Meeting, highlighting the dual mechanism of action of its small molecule TPST-1495. The data indicate that TPST-1495 effectively promotes anti-tumor activity in preclinical studies by inhibiting EP2 and EP4 receptors in the prostaglandin pathway. The company plans to initiate combination studies with pembrolizumab and conduct expansion studies focusing on specific cancer types in early 2022. This research underlines TPST-1495's potential in enhancing anti-tumor immunity and improving patient outcomes.
Tempest Therapeutics (TPST) announced the start of a Phase 1b/2 clinical trial for its TPST-1120 therapy in collaboration with Roche, aimed at treating hepatocellular carcinoma (HCC). The company reported a cash position of $59.8 million as of September 30, 2021, up from $18.8 million in December 2020, primarily due to a merger. However, net losses were $8.1 million for Q3 2021, increasing from $5.4 million in Q3 2020. Research and development expenses rose to $4.6 million, reflecting increased operational costs. Tempest anticipates sufficient resources to continue operations into Q2 2023.
Tempest Therapeutics (Nasdaq: TPST) announced participation in two investor conferences this November. The company will present at the Jefferies London Healthcare Conference on November 18, 2021, with an on-demand presentation available at 8:00 a.m. GMT. Additionally, they will engage in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, available at 10:00 a.m. ET. Tempest is focused on developing innovative oncology therapeutics, including TPST-1495 and TPST-1120, which are currently in Phase 1 studies.
Tempest Therapeutics (Nasdaq: TPST) announced that the U.S. Patent Office has issued multiple patents for its therapeutic candidate TPST-1495, an orally available small molecule targeting EP2 and EP4 receptors in the PGE2 pathway. This dual antagonist shows enhanced potency in pre-clinical studies compared to single EP4 inhibitors and could address tumor progression and immune suppression linked to PGE2 signaling. The patent portfolio, now including U.S. Patent Numbers 10,968,201 and 11,066,405, strengthens Tempest's IP for TPST-1495's use, which is currently in Phase 1 clinical trials for advanced solid tumors.
FAQ
What is the current stock price of Tempest Therapeutics (TPST)?
What is the market cap of Tempest Therapeutics (TPST)?
What does Tempest Therapeutics, Inc. do?
What are Tempest Therapeutics' main product candidates?
Who developed Tempest Therapeutics' molecules?
What makes Tempest Therapeutics' pipeline unique?
Who are the key contacts for investor and media inquiries?
What type of cancers does Tempest Therapeutics target?
What is the core mission of Tempest Therapeutics?
What recent achievements has Tempest Therapeutics made?
Who supports Tempest Therapeutics financially?
How can I get the latest updates on Tempest Therapeutics?
